Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2023年 / 20卷 / 12期
关键词：
CISPLATIN; CHEMOTHERAPY; CANCER; UNFIT;
D O I：
10.1038/s41571-023-00814-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin-ineligible, herein we highlight key clinical outcomes with this combination based on results from Cohort K of the pivotal phase Ib/II EV-103 trial. We also discuss treatment sequencing, de-escalation strategies and toxicity management as EV-pembrolizumab becomes widely used in clinical practice.
引用
收藏
页码：818 / 819
页数：2
相关论文
共 50 条
  • [21] The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial
    Hoimes, Christopher J.
    Rosenberg, Jonathan E.
    Petrylak, Daniel P.
    Carret, Anne-Sophie
    Melhem-Bertrandt, Amal
    Flaig, Thomas W.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 43 - 43
  • [22] EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
    Hoimes, Christopher J.
    Rosenberg, Jonathan E.
    Petrylak, Daniel Peter
    Carret, Anne-Sophie
    Melhem-Bertrandt, Amal
    Flaig, Thomas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin, David J.
    Kalebasty, Arash Rezazadeh
    Prasad, Vinay
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 313 - 315
  • [24] A new standard of care for advanced-stage urothelial carcinoma
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2024, 21 : 336 - 336
  • [25] A new standard of care for advanced-stage urothelial carcinoma
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (05) : 336 - 336
  • [26] A CASE OF ENFORTUMAB VEDOTIN TOXICITY IN A PATIENT WITH ADVANCED UROTHELIAL CELL CARCINOMA
    Grigsby, Charles
    Thebert, Alexander
    Pijut, Kyle
    Woodward, Blake
    Bastin, Melissa Thompson
    Soper, Melissa
    Fozzard, Andrew
    CRITICAL CARE MEDICINE, 2024, 52
  • [27] Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
    Furubayashi, Nobuki
    Negishi, Takahito
    Mochida, Manabu
    Kijima, Atsuhiro
    Katsuki, Harumichi
    Nakamura, Motonobu
    IN VIVO, 2025, 39 (01): : 411 - 418
  • [28] Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
    Chan, Kok Hoe
    Shu, Tung
    Al Shaarani, Majd
    Cen, Putao
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2024, 12
  • [29] Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer
    Guarino, Adriana
    Santoni, Matteo
    Catalano, Martina
    Roviello, Giandomenico
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2025, 19
  • [30] The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria
    Apolo, A. B.
    Bellmunt, J.
    Cordes, L.
    Gupta, S.
    Powles, T.
    Rosenberg, J. E.
    Van Der Heijden, M. S.
    ESMO OPEN, 2024, 9 (09)
12345